Skip to main content
SpringerLink
Log in

Procalcitonin serum levels in stage 5 chronic kidney disease children on hemodialysis

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Background

Infections are responsible for morbidity and mortality in children on hemodialysis (HD). Procalcitonin (PCT) is rarely used in this population, even though it is an efficient biomarker of infection and sepsis. Our aim was to study PCT baseline level in uninfected children with stage 5 chronic kidney disease (CKD 5) on HD, and determine how to use it in this population.

Methods

Prospective observational study including 40 uninfected children on classical HD or hemodiafiltration (HDF) in three pediatric HD centers in the Paris region. PCT was monitored before and after three consecutive sessions within 1 week.

Results

Median pre-dialysis PCT was 0.60 ng/mL [0.36–1.15], median post-dialysis PCT was 0.23 ng/mL [0.10–0.47], PCT reduction rate was 59.8% [37.5–75.8]. Seventy percent of pre-dialysis PCT were <1 ng/mL. Anuric patients had higher pre-dialysis PCT than those with residual urine output (0.70 [0.42–1.30] vs. 0.48 [0.30–0.93] ng/mL, p=0.01). HDF was more efficient than HD to clear PCT during sessions (reduction rate 75% [67–80] vs. 37 [31–50]), p<0.001).

Conclusion

PCT levels in pediatric HD patients without infection are higher than normal, but this increase is relatively moderate compared to massive increases of PCT in children with bacterial infections on HD. If PCT is measured after dialysis sessions, the specific technique-dependent reduction rates should be taken into consideration. Moderately increased PCT levels around 2 ng/ml should be interpreted with caution; however, higher PCT serum levels can be used to motivate rapid start of antibiotic treatment in pediatric HD patients.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chesnaye N, Bonthuis M, Schaefer F, Groothoff JW, Verrina E, Heaf JG, Jankauskiene A, Lukosiene V, Molchanova EA, Mota C, Peco-Antić A, Ratsch I-M, Bjerre A, Roussinov DL, Sukalo A, Topaloglu R, Van Hoeck K, Zagozdzon I, Jager KJ, Van Stralen KJ, ESPN/ERA–EDTA registry (2014) Demographics of paediatric renal replacement therapy in Europe: a report of the ESPN/ERA-EDTA registry. Pediatr Nephrol 29:2403–2410. https://doi.org/10.1007/s00467-014-2884-6

    Article  PubMed  Google Scholar 

  2. Agence de la Biomédecine (2017) Rapport annuel 2017 - Registre REIN - Registre français des traitements de suppléance de l’insuffisance rénale chronique

  3. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79:1605–1608. https://doi.org/10.1210/jcem.79.6.7989463

    Article  CAS  PubMed  Google Scholar 

  4. Stocker M, van Herk W, el Helou S, Dutta S, Fontana MS, Schuerman FABA, van den Tooren-de Groot RK, Wieringa JW, Janota J, van der Meer-Kappelle LH, Moonen R, Sie SD, de Vries E, Donker AE, Zimmerman U, Schlapbach LJ, de Mol AC, Hoffman-Haringsma A, Roy M, Tomaske M, Kornelisse RF, van Gijsel J, Visser EG, Willemsen SP, van Rossum AMC, Bakry A, Dutta S, el Helou S, Kalaniti K, Pogorzelski D, Alliston S, Roy M, Grey V, Hauff K, Hill S, Kittanakom S, Janota J, Visnovska M, Fontana M, Lanz N, Stocker M, Glauser D, Zimmerman U, Tomaske M, Nelle M, Schlapbach L, Schuerman F, Sie S, van Weissenbruch M, van den Dungen F, Strik M, van den Tooren-de H, van Rossum GA, Batstra M, van der Meer-Kappelle L, de Vries E, de Mol A, Bolt-Wieringa J, Stok D, Moonen R, Donker S, van Gijsel J, Gondriet I, van Herk W, Hoekstein S, Hofhuis M, Hop W, de Ligt L, Manai B, Kornelisse R, de Rijke Y, van Rossum A, Siiskonen S, van der Velden J, Visser E, van Wijk JA, Willemsen S, van der Geijn G, Haringsma A, Andriessen P, Broeren M, Donker A (2017) Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet 390:871–881. https://doi.org/10.1016/S0140-6736(17)31444-7

    Article  CAS  PubMed  Google Scholar 

  5. Herget-Rosenthal S, Marggraf G, Pietruck F, Hüsing J, Strupat M, Philipp T, Kribben A (2001) Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 16:975–979. https://doi.org/10.1093/ndt/16.5.975

    Article  CAS  PubMed  Google Scholar 

  6. Goldstein SL, Sorof JM, Brewer ED (1999) Natural logarithmic estimates of Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 33:518–522. https://doi.org/10.1016/S0272-6386(99)70189-7

    Article  CAS  PubMed  Google Scholar 

  7. Lee WS, Kang DW, Back JH, Kim HL, Chung JH, Shin BC (2015) Cutoff value of serum procalcitonin as a diagnostic biomarker of infection in end-stage renal disease patients. Korean J Intern Med 30:198. https://doi.org/10.3904/kjim.2015.30.2.198

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wu S, Liang C, Zhang Y, Hu W (2020) Elevated serum procalcitonin level in patients with chronic kidney disease without infection: a case-control study. J Clin Lab Anal 34:e23065. https://doi.org/10.1002/jcla.23065

    Article  CAS  PubMed  Google Scholar 

  9. Trimarchi H, Dicugno M, Muryan A, Lombi F, Iturbe L, Raña MS, Young P, Nau K, Iriarte R, Pomeranz V, Forrester M, Karl A, Alonso M (2013) Pro-calcitonin and inflammation in chronic hemodialysis. Medicina (B Aires) 73:411–416

    CAS  Google Scholar 

  10. Kubo S, Iwasaki M, Horie M, Matsukane A, Hayashi T, Tanaka Y, Hase H, Joki N (2019) Biological variation of procalcitonin levels in hemodialysis patients. Clin Exp Nephrol 23:402–408. https://doi.org/10.1007/s10157-018-1639-2

    Article  CAS  PubMed  Google Scholar 

  11. Lorton F, Veinberg F, Ielsch D, Deschênes G, Bensman A, Ulinski T (2007) Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol 22:430–435. https://doi.org/10.1007/s00467-006-0304-2

    Article  PubMed  Google Scholar 

  12. Meisner M, Lohs T, Huettemann E, Schmidt J (2001) The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 18:79–87. https://doi.org/10.1046/j.0265-0215.2000.00783.x

    Article  CAS  PubMed  Google Scholar 

  13. Meisner M, Schmidt J, Hüttner H, Tschaikowsky K (2000) The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 26(Suppl 2):S212–S216. https://doi.org/10.1007/BF02900740

    Article  PubMed  Google Scholar 

  14. Demir NA, Sumer S, Celik G, Afsar RE, Demir LS, Ural O (2018) How should procalcitonin and C-reactive protein levels be interpreted in haemodialysis patients?: PCT and CRP in haemodialysis patients. Intern Med J 48:1222–1228. https://doi.org/10.1111/imj.13952

    Article  CAS  PubMed  Google Scholar 

  15. Jiang L, Shao X, Xing W, Sun Y (2019) Biomarkers and risk factors for sepsis in stage 5 chronic kidney disease: a retrospective case–control study. Int Urol Nephrol 51:691–698. https://doi.org/10.1007/s11255-018-2035-2

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology Unit, Armand Trousseau Hospital, APHP, DMU Origyne, Sorbonne Université, 75012, Paris, France

    Antoine Mouche, Cyrielle Parmentier, Claire Herbez Rea, Jean Daniel Delbet & Tim Ulinski

  2. Sorbonne Université, Paris, France

    Cyrielle Parmentier, Claire Herbez Rea & Tim Ulinski

  3. Pediatric Nephrology Unit, Robert Debré Hospital, APHP, Paris, France

    Thérèsa Kwon

  4. Pediatric Nephrology Unit, Necker Enfants Malades Hospital, APHP, Paris, France

    Olivia Boyer

Authors
  1. Antoine Mouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cyrielle Parmentier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claire Herbez Rea
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thérèsa Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivia Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean Daniel Delbet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tim Ulinski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tim Ulinski.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(PPT 114 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mouche, A., Parmentier, C., Herbez Rea, C. et al. Procalcitonin serum levels in stage 5 chronic kidney disease children on hemodialysis. Pediatr Nephrol 36, 2405–2409 (2021). https://doi.org/10.1007/s00467-021-04966-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-021-04966-4

Keywords

Search

Navigation